dc.contributor.author | Loveday, C | |
dc.contributor.author | Litchfield, K | |
dc.contributor.author | Proszek, PZ | |
dc.contributor.author | Cornish, AJ | |
dc.contributor.author | Santo, F | |
dc.contributor.author | Levy, M | |
dc.contributor.author | Macintyre, G | |
dc.contributor.author | Holryod, A | |
dc.contributor.author | Broderick, P | |
dc.contributor.author | Dudakia, D | |
dc.contributor.author | Benton, B | |
dc.contributor.author | Bakir, MA | |
dc.contributor.author | Hiley, C | |
dc.contributor.author | Grist, E | |
dc.contributor.author | Swanton, C | |
dc.contributor.author | Huddart, R | |
dc.contributor.author | Powles, T | |
dc.contributor.author | Chowdhury, S | |
dc.contributor.author | Shipley, J | |
dc.contributor.author | O'Connor, S | |
dc.contributor.author | Brenton, JD | |
dc.contributor.author | Reid, A | |
dc.contributor.author | de Castro, DG | |
dc.contributor.author | Houlston, RS | |
dc.contributor.author | Turnbull, C | |
dc.date.accessioned | 2020-05-18T14:15:34Z | |
dc.date.issued | 2020-05-04 | |
dc.identifier.citation | Nature communications, 2020, 11 (1), pp. 2189 - ? | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3613 | |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.doi | 10.1038/s41467-020-15768-x | |
dc.description.abstract | While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms, we undertake whole exome sequencing and copy number analysis in 40 tumours from 26 cases with platinum-resistant TGCT, and combine this with published genomic data on an additional 624 TGCTs. We integrate analyses for driver mutations, mutational burden, global, arm-level and focal copy number (CN) events, and SNV and CN signatures. Albeit preliminary and observational in nature, these analyses provide support for a possible mechanistic link between early driver mutations in RAS and KIT and the widespread copy number events by which TGCT is characterised. | |
dc.format | Electronic | |
dc.format.extent | 2189 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasms, Germ Cell and Embryonal | |
dc.subject | Testicular Neoplasms | |
dc.subject | Genetic Predisposition to Disease | |
dc.subject | Platinum | |
dc.subject | Organoplatinum Compounds | |
dc.subject | ras Proteins | |
dc.subject | Genomics | |
dc.subject | Signal Transduction | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Mutation | |
dc.subject | Male | |
dc.subject | Proto-Oncogene Proteins c-kit | |
dc.subject | DNA Copy Number Variations | |
dc.subject | Whole Exome Sequencing | |
dc.title | Genomic landscape of platinum resistant and sensitive testicular cancers. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-03-23 | |
rioxxterms.versionofrecord | 10.1038/s41467-020-15768-x | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-05-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature communications | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Cancer Genomics | |
icr.researchteam | Sarcoma Molecular Pathology | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
dc.contributor.icrauthor | Litchfield, Kevin | |
dc.contributor.icrauthor | Cornish, Alexander | |
dc.contributor.icrauthor | Broderick, Peter | |
dc.contributor.icrauthor | Huddart, Robert | |
dc.contributor.icrauthor | Shipley, Janet | |
dc.contributor.icrauthor | Houlston, Richard | |
dc.contributor.icrauthor | Turnbull, Clare | |